|
WO2021006305A1
|
|
APTAMER FOR TGF-β1 AND USE OF SAME
|
|
WO2020241493A1
|
|
Drug for the treatment of disorders related to abnormalities in bone formation and bone metabolism
|
|
WO2020204151A1
|
|
Aptamer to fgf9 and use thereof
|
|
SG11202012933QA
|
|
Aptamer preparation
|
|
AU2018376416A1
|
|
Anti-chymase aptamer and use for same
|
|
AU2018363996A1
|
|
Aptamer for ADAMTS5, and use for aptamer for ADAMTS5
|
|
CN106232817A
|
|
In conjunction with autocrine motility factor and the fit and application of the biologic activity suppressing autocrine motility factor
|
|
CN106164267A
|
|
The fit of the biologic activity of autocrine motility factor and application thereof is suppressed with autocrine motility factor by being combined
|
|
AU2015235020A1
|
|
Aptamer for FGF2 and use thereof
|
|
EP2924120A1
|
|
Anti-midkine aptamer and applications thereof
|
|
EP2762569A1
|
|
Ngf aptamer and application thereof
|
|
WO2013186857A1
|
|
Aptamer to fgf2 and use thereof
|
|
SI2551346T1
|
|
Aptamer for ngf and use thereof
|
|
TW201103983A
|
|
Aptamer against chymase and use thereof
|
|
WO2009063998A1
|
|
Nucleic acid having hydrophobic substance added thereto, and use thereof
|
|
UA100847C2
|
|
Aptamer against midkain and its using
|
|
JP2008167688A
|
|
Ribonucleic acid combined with mtg8 taf domain
|
|
TW200825097A
|
|
Nucleic acid capable of binding to immunoglobulin G and use thereof
|
|
CN101258241A
|
|
Nucleic acid capable of binding to immunoglobulin G and use thereof
|
|
KR20080036595A
|
|
Nucleic acid capable of binding to immunoglobulin g and use thereof
|
